Patients at increased risk of MRSA infection
For patients with periorbital cellulitis who are systemically well and have concurrent sinusitis or risk factors for Hib infection and who are at increased risk of MRSA infection, use:
trimethoprim+sulfamethoxazole 160+800 mg (child 1 month or older: 4+20 mg/kg up to 160+800 mg) orally, 12-hourly. For dosage adjustment in adults with kidney impairment, see trimethoprim+sulfamethoxazole dosage adjustment. See advice on patient review, and modification and duration of therapy. trimethoprim + sulfamethoxazole trimethoprim+sulfamethoxazole trimethoprim+sulfamethoxazole